Allogeneic hematopoietic stem cell transpalntation using Thymoglobulin for patients with T-cell malignancy

Allogeneic hematopoietic stem cell transpalntation using Thymoglobulin for patients with T-cell malignancy - AlloHSCT with ATG for T-cell malignancy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015736

Enrollment

Registered

2014-11-21

Start date

2014-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T-cell malignancy

Interventions

Conditioning regimen using Thymoglobulin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) HSCT using a HLA matched related donor, or HLA at least 6/8 matched unrelated donor (2) T-cell malignancy, including B-cell lymphoma expressing T cell marker (3) Disease status no complete remission (4) 18<=age<=70 (5) ECOG PS 0 or 1 (6) informed consent (7) those who are expected to survive at least 3 months

Exclusion criteria

Exclusion criteria: (1) severe organ failure (2) uncontrolled hypertension (3) HIV infection (4) uncontrolled active infection (5) uncontrolled CNS invasion (6) pregnancy (7) psychological disorder (8) allergy to drugs used in this study (9) if the physician consider as inappropriate

Design outcomes

Primary

Measure	Time frame
Probability of survival with engraftment at 60 days after allogeneic HSCT	—

Countries

Japan

Contacts

Public ContactShigeo Fuji

National Cancer Center Hospital Division of Hematopoietic Stem Cell Transplantation

sfuji@ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026